WO2009106960A2 - Stable compositions of lamivudine, tenofovir and efavirenz - Google Patents
Stable compositions of lamivudine, tenofovir and efavirenz Download PDFInfo
- Publication number
- WO2009106960A2 WO2009106960A2 PCT/IB2009/000352 IB2009000352W WO2009106960A2 WO 2009106960 A2 WO2009106960 A2 WO 2009106960A2 IB 2009000352 W IB2009000352 W IB 2009000352W WO 2009106960 A2 WO2009106960 A2 WO 2009106960A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lamivudine
- tenofovir
- efavirenz
- sodium
- granules
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Definitions
- the present invention relates to stable bilayered tablets of combination of antiretroviral agents. More particularly, the present invention relates to stable dosage forms comprising lamivudine, tenofovir disoproxil fumarate and efavirenz prepared by wet granulation.
- HIV human immunodeficiency virus
- AIDS acquired immunodeficiency syndrome
- Anti-retroviral drugs such as reverse transcriptase inhibitors and viral protease inhibitors, have been used to treat HIV infection. These treatments can effectively suppress viral production when used in combinations known as HAART (Highly Active Anti-Retroviral Therapy).
- Tenofovir disoproxil fumarate (a prodrug of tenofovir) is a fumaric acid salt of bis-isopropoxycarbonyloxymethyl ester derivative of tenofovir.
- tenofovir disoproxil fumarate (tenofovir DF) is 9-[(R)-2- [[bis[[(isopropoxycarbonyl)oxy]methoxy]phosphinyl]methoxy]propyl]adenine fumarate and is commercially available as tablets under the trade name Viread®.
- Tenofovir disoproxil fumarate was first disclosed in US patent No. 5,922,695.
- lamivudine is (2R,cis)-4-amino-l-(2-hydroxymethyl-l,3- oxathiolan-5-yl)-(lH)-pyrimidin-2-one and is commercially available as tablets and oral solution under the trade name Epivir ® .
- Lamivudine and method of treating HIV using lamivudine was first disclosed in US 5,047,407.
- One substantial and persistent problem in the treatment of AIDS has been the ability of the HIV virus to develop resistance to the individual therapeutic agents employed to treat the disease.
- a need remains for an efficacious and long lasting therapy for AIDS which lowers HIV viral levels of patients to undetectable levels and raises CD4 cell counts for prolonged periods of time without the development of resistance.
- efavirenz is (S)-6-chloro-4-(cyclopropylethynyl)-l,4- dihydro-4-(trifluoromethyl)-2H-3,l-benzoxazin- 2-one and is commercially available as tablets and capsules under the trade name Sustiva ® .
- Efavirenz and method of treating HIV using efavirenz was first disclosed in US 5,519,021.
- FDCs when compared to the separate ARV regimens are ease of use, better adherences to the dosage schedules, reduced risk of drug resistance and increased affordability.
- Combination therapy reduces the daily dosages to be taken by patients and simplifies dosing schedule thereby increases patient compliance.
- US 5,627,186 disclose combination of lamivudine and zidovudine for treating HIV infections.
- US 6,417,191 discloses combination of abacavir and lamivudine; abacavir, lamivudine and zidovudine for treating HIV infections.
- US 2004/0224917 discloses therapeutic combinations of emtricitabine and tenofovir DF useful for treatment of HIV infections.
- US 2007/0077295 discloses composition of tenofovir DF and emtricitabine prepared by dry granulation for treating HIV infections.
- US 2007/099902 discloses a multi component unitary dosage form comprising tenofovir DF and emtricitabine in first component and efavirenz in second component useful for treatment of HIV infections.
- ZA 2001/10500 discloses pharmaceutical composition of lamivudine, zidovudine and nevirapine and process, which comprises wet granulating lamivudine, zidovudine, nevirapine and diluent with water; drying, sizing and blending the granules with disintegrant; lubricating the granules; and compressing the lubricated granules into tablets.
- WO 2004/089382 discloses combination of lamivudine, zidovudine and efavirenz for treating HIV infections.
- WO 2004/089383 discloses combination of lamivudine, stavudine and efavirenz for treating HIV infections.
- WO 2006/001029 discloses a process for preparing a composition of lamivudine, zidovudine and nevirapine and process which comprises granulating lamivudine, zidovudine, nevirapine, microcrystalline cellulose, starch, croscarmellose sodium with a solution of polyvinylpyrrolidone k-30 and drying the granules, blending the dried granules with magnesium stearate, croscarmellose sodium, colloidal anhydrous silica, crospovidone and compressing the blend into tablets.
- WO 2006/086865 discloses a composition comprising lamivudine, zidovudine and nevirapine in a single coated tablet prepared by dry granulation.
- WO 2006/1 14709 discloses a composition comprising lamivudine, zidovudine and nevirapine prepared by a granulation process comprising the steps of preparing granules of lamivudine plus zidovudine and granules of nevirapine separately, blending the obtained granules with excipients and finally compressing the granules into tablets.
- WO 2007/026156 discloses a composition comprising lamivudine, stavudine and nevirapine for pediatric treatment of viral infections.
- WO 2007/068934 discloses a bilayered formulation comprising lamivudine and tenofovir. It is disclosed in this publication that lamivudine and tenofovir DF when intimately mixed to form a single layered tablet showed undesirable properties in stability testing. The appearance of tablets changed to brown colour at controlled room temperature (25 0 C) and even at accelerated temperature (4O 0 C). Inorder to avoid the discoloration, lamivudine and tenofovir DF are formulated as a bilayered tablet. This patent publication further discloses a kit comprising bilayered tablet of lamivudine and tenofovir as first formulation and efavirenz tablet as second formulation.
- WO 2008/043829 discloses combination of emtricitabine, tenofovir and nevirapine for once a day administration.
- WO 2008/096369 discloses a formulation comprising lamivudine and tenofovir DF prepared by granulating tenofovir DF seperately by dry granulation and blending the granules with extragranular lamivudine and finally compressing into tablets.
- This publication further discloses monolithic tablets comprising emtricitabine/lamivudine, tenofovir DF and efavirenz.
- compositions of various combinations of antiretroviral agents prepared as single and/or double layered tablets disclose compositions of various combinations of antiretroviral agents prepared as single and/or double layered tablets.
- stable dosage form comprising lamivudine, tenofovir and efavirenz.
- the inventors of the present invention have surprisingly found that when lamivudine, tenofovir DF and efavirenz are granulated separately and compressed into a bilayered tablet results in a stable dosage form.
- the main objective of the present invention is to provide a stable dosage form comprising lamivudine, tenofovir disoproxil fumarate and efavirenz and process for preparing the dosage form.
- Yet another objective of the present invention is to provide stable dosage form of lamivudine, tenofovir disoproxil fumarate and efavirenz in such a way that it will comply with the reference products of each of these approved individual drugs in terms of in vitro parameters like dissolution, disintegration etc. and in vivo parameters like bioequivalence.
- the present invention provides stable bilayered tablets comprising lamivudine, tenofovir and efavirenz prepared by wet granulation process.
- the stable dosage form further comprises one or more excipients selected from diluents, binders, disintegrants, surfactants, glidants and lubricants.
- Efavirenz practically insoluble in water and is freely soluble in methanol.
- the commercially available tablets of efavirenz i.e available in the US under the trade name Sustiva® tablets and capsules contain sodium lauryl sulfate as a solubilizer.
- the inventors of the present invention found that when tablets containing lamivudine, tenofovir and efavirenz are prepared using single step process, tenofovir degrades on storage. Initial efforts to simply combine lamivudine, tenofovir and efavirenz into a unitary composition failed to produce a chemically stable tablet.
- Suitable diluents of the present invention are selected from mannitol, lactose, microcrystalline cellulose, maltitol, sorbitol, maltodextrin, maltose, starch, calcium carbonate, calcium phosphate dibasic, calcium sulfate or a combination thereof.
- the diluent may be used in the range of 3-50% by weight of the tablet.
- Suitable binders of the present invention are selected from hydroxy propyl cellulose, hydroxypropyl methylcellulose, gelatin, hydroxy ethyl cellulose, povidone, starch and methylcellulose or a combination thereof.
- the binder may be used in the range of 0.5-10% by weight of the tablet.
- Suitable disintegrants of the present invention are selected from sodium starch glycolate, croscarmellose sodium, crospovidone, starch, hydroxypropyl cellulose, magnesium aluminum silicate, pregelatinized starch or a combination thereof.
- the disintegrant may be used in the range of 1-10% by weight of the tablet.
- Suitable surfactants of the present invention are selected from sodium lauryl sulphate, polysorbate, sorbitan monolaurate, polyoxyethylene- polyoxypropylene block copolymer (poloxamer), polyethylene glycol derivatives, cetyl alcohol or a combination thereof.
- the surfactant may be used in the range of 0.01-1% by weight of the tablet.
- Suitable glidants of the present invention are selected from magnesium trisilicate, talc, tribasic calcium phosphate, glyceryl monostearate, glyceryl stearate and silica dioxide or a combination thereof.
- the glidant may be used in the range of 0.1-2% by weight of the tablet.
- Suitable lubricants of the present invention are selected from calcium stearate, magnesium stearate, hydrogenated vegetable oil, stearic acid, magnesium aluminum silicate, sodium stearyl fumarate, glyceryl behenate or a combination thereof.
- the lubricant may be used in the range of 0.1-5% by weight of the tablet.
- Tenofovir as used herein refers to tenofovir disoproxil fumarate.
- the stable bilayered tablets comprise 50-500 mg of lamivudine, 50-500 mg of tenofovir and 100-600mg of efavirenz.
- the stable bilayered tablets comprise i) compressed granules of lamivudine, tenofovir, 2-20% w/w of diluent selected from microcrystalline cellulose, lactose and mannitol; 1-5% w/w of disintegrant selected from croscarmellose sodium, crospovidone and sodium starch glycolate prepared by wet granulation in first layer and ii) compressed granules of efavirenz, 5-20% w/w of diluent selected from microcrystalline cellulose, lactose and mannitol, 1-5% w/w of disintegrant selected from croscarmellose sodium, crospovidone and sodium starch glycolate; 0.5 to 5% w/w of binder selected form hydroxy propyl cellulose, hydroxypropyl methylcellulose, povidone; sodium lauryl sulfate in 0.1 to 2% w/w of sodium lauryl sulfate prepared by
- the stable bilayered tablets comprise i) compressed granules of lamivudine, efavirenz, 2-20% w/w of diluent selected from microcrystalline cellulose, lactose and mannitol; 1-5% w/w of disintegrant selected from croscarmellose sodium, crospovidone and sodium starch glycolate; .5 to 5% w/w of binder selected form hydroxy propyl cellulose, hydroxypropyl methylcellulose, povidone; sodium lauryl sulfate in 0.1 to 2% w/w of sodium lauryl sulfate prepared by wet granulation in the first layer and ii) compressed granules of tenofovir, 5-20% w/w of diluent selected from microcrystalline cellulose, lactose and mannitol, 1-5% w/w of disintegrant selected from croscarmellose sodium, crospovidone and sodium starch
- stable bilayered tablets comprising lamivudine, tenofovir and efavirenz are prepared by wet granulation process using solvents, which comprises the steps of: a) preparing granules comprising lamivudine, tenofovir and one or more pharmaceutically acceptable excipients, b) preparing granules of efavirenz and one or more pharmaceutically acceptable excipients, c) separately blending and lubricating the granules of step (a) and (b), with extragranular excipients and d) finally compressing the granules into bi-layer tablets.
- stable bilayered tablets comprising lamivudine, tenofovir and efavirenz are prepared by wet granulation process using solvents, which comprises the steps of: a) preparing granules comprising lamivudine, efavirenz and one or more pharmaceutically acceptable excipients, b) blending and lubricating the granules of step (a) with extragranular excipients, c) preparing granules of tenofovir and one or more pharmaceutically acceptable excipients, d) blending and lubricating the granules of step (c) with extragranular excipients, e) compressing the lubricated granules of step (b) and step (d) into bi-layer tablets.
- stable bilayered tablets comprising lamivudine, tenofovir and efavirenz are prepared by wet granulation process using solvents, which comprises the steps of: a) preparing granules comprising lamivudine and one or more pharmaceutically acceptable excipients,' b) preparing granules comprising tenofovir and one or more pharmaceutically acceptable excipients, c) preparing granules of efavirenz and one or more pharmaceutically acceptable excipients, d) blending the granules of step (a) and (b) or step (a) and (c), with extragranular excipients and e) processing the blend of (a) and (b) or (a) and (c) with the blend of (c) or (b), e) finally compressing the granules into bi-layer tablets.
- the solvents used for granulation process may be selected from water, isopropyl alcohol
- the tablets of the present invention may optionally be coated to prevent the degradation of lamivudine from light with coating polymers.
- Suitable film forming polymers used according to the present invention are selected from hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxy ethyl cellulose, xanthan gum and the like or a combination there of.
- the stable dosage form of the present invention is used for the treatment or prevention of symptoms of HIV infection in an infected individual.
- Dissolution profile of bilayered tablets of lamivudine, tenofovir and efavirenz prepared according to example 3 was carried out in water with 2% SLS as dissolution medium using USP Apparatus II with 1000 ml at 75 rpm speed.
- the release profile (% drug released in min) is given in Table 1.
- Dissolution profile of bilayered tablets of lamivudine, tenofovir and efavirenz prepared according to example 4 was carried out in water with 2% SLS as dissolution medium using USP Apparatus II with 1000 ml at 75 rpm speed.
- the release profile (% drug released in min) is given in Table 2.
- the bilayered tablets of lamivudine, tenofovir and efavirenz tablets according to the present invention were found to be stable.
- the stability data obtained after 1 month at 45°C/75RH is shown in Table 3.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to stable bilayered tablets of combination of antiretroviral agents. More particularly, the present invention relates to stable dosage forms comprising lamivudine, tenofovir disoproxil fumarate and efavirenz prepared by wet granulation.
Description
STABLE COMPOSITIONS OF LAMIVUDINE, TENOFOVIR AND
EFAVIRENZ
Field of the invention The present invention relates to stable bilayered tablets of combination of antiretroviral agents. More particularly, the present invention relates to stable dosage forms comprising lamivudine, tenofovir disoproxil fumarate and efavirenz prepared by wet granulation.
Background of the invention The human immunodeficiency virus (HIV) is the causative agent of acquired immunodeficiency syndrome (AIDS). This disease is characterized by the destruction of the immune system, particularly of the CD4 and T-cell making the host susceptible to opportunistic infections. HIV is also associated with a precursor AIDS-related complex (ARC), a syndrome characterized by symptoms such as persistent generalized lymphadenopathy, fever and weight loss.
Anti-retroviral drugs, such as reverse transcriptase inhibitors and viral protease inhibitors, have been used to treat HIV infection. These treatments can effectively suppress viral production when used in combinations known as HAART (Highly Active Anti-Retroviral Therapy). Tenofovir disoproxil fumarate (a prodrug of tenofovir) is a fumaric acid salt of bis-isopropoxycarbonyloxymethyl ester derivative of tenofovir. Chemically, tenofovir disoproxil fumarate (tenofovir DF) is 9-[(R)-2- [[bis[[(isopropoxycarbonyl)oxy]methoxy]phosphinyl]methoxy]propyl]adenine fumarate and is commercially available as tablets under the trade name Viread®. Tenofovir disoproxil fumarate was first disclosed in US patent No. 5,922,695.
Chemically, lamivudine is (2R,cis)-4-amino-l-(2-hydroxymethyl-l,3- oxathiolan-5-yl)-(lH)-pyrimidin-2-one and is commercially available as tablets and oral solution under the trade name Epivir®. Lamivudine and method of treating HIV using lamivudine was first disclosed in US 5,047,407. One substantial and persistent problem in the treatment of AIDS has been the ability of the HIV virus to develop resistance to the individual therapeutic agents employed to treat the disease. Thus, a need remains for an efficacious and
long lasting therapy for AIDS which lowers HIV viral levels of patients to undetectable levels and raises CD4 cell counts for prolonged periods of time without the development of resistance. Hence, there is a need to develop combination of drugs to treat AIDS called as fixed dose combinations (FDC). Chemically, efavirenz is (S)-6-chloro-4-(cyclopropylethynyl)-l,4- dihydro-4-(trifluoromethyl)-2H-3,l-benzoxazin- 2-one and is commercially available as tablets and capsules under the trade name Sustiva®. Efavirenz and method of treating HIV using efavirenz was first disclosed in US 5,519,021.
The various advantages of FDCs when compared to the separate ARV regimens are ease of use, better adherences to the dosage schedules, reduced risk of drug resistance and increased affordability. Combination therapy reduces the daily dosages to be taken by patients and simplifies dosing schedule thereby increases patient compliance.
Following are few patents/publications, which disclose combinations of antiretrovirals.
US 5,627,186 disclose combination of lamivudine and zidovudine for treating HIV infections.
US 6,417,191 discloses combination of abacavir and lamivudine; abacavir, lamivudine and zidovudine for treating HIV infections. US 2004/0224917 discloses therapeutic combinations of emtricitabine and tenofovir DF useful for treatment of HIV infections.
US 2007/0077295 discloses composition of tenofovir DF and emtricitabine prepared by dry granulation for treating HIV infections.
US 2007/099902 discloses a multi component unitary dosage form comprising tenofovir DF and emtricitabine in first component and efavirenz in second component useful for treatment of HIV infections.
ZA 2001/10500 discloses pharmaceutical composition of lamivudine, zidovudine and nevirapine and process, which comprises wet granulating lamivudine, zidovudine, nevirapine and diluent with water; drying, sizing and blending the granules with disintegrant; lubricating the granules; and compressing the lubricated granules into tablets.
WO 2004/089382 discloses combination of lamivudine, zidovudine and efavirenz for treating HIV infections.
WO 2004/089383 discloses combination of lamivudine, stavudine and efavirenz for treating HIV infections. WO 2006/001029 discloses a process for preparing a composition of lamivudine, zidovudine and nevirapine and process which comprises granulating lamivudine, zidovudine, nevirapine, microcrystalline cellulose, starch, croscarmellose sodium with a solution of polyvinylpyrrolidone k-30 and drying the granules, blending the dried granules with magnesium stearate, croscarmellose sodium, colloidal anhydrous silica, crospovidone and compressing the blend into tablets.
WO 2006/086865 discloses a composition comprising lamivudine, zidovudine and nevirapine in a single coated tablet prepared by dry granulation.
WO 2006/1 14709 discloses a composition comprising lamivudine, zidovudine and nevirapine prepared by a granulation process comprising the steps of preparing granules of lamivudine plus zidovudine and granules of nevirapine separately, blending the obtained granules with excipients and finally compressing the granules into tablets.
WO 2007/026156 discloses a composition comprising lamivudine, stavudine and nevirapine for pediatric treatment of viral infections.
WO 2007/068934 discloses a bilayered formulation comprising lamivudine and tenofovir. It is disclosed in this publication that lamivudine and tenofovir DF when intimately mixed to form a single layered tablet showed undesirable properties in stability testing. The appearance of tablets changed to brown colour at controlled room temperature (250C) and even at accelerated temperature (4O0C). Inorder to avoid the discoloration, lamivudine and tenofovir DF are formulated as a bilayered tablet. This patent publication further discloses a kit comprising bilayered tablet of lamivudine and tenofovir as first formulation and efavirenz tablet as second formulation. WO 2008/043829 discloses combination of emtricitabine, tenofovir and nevirapine for once a day administration.
WO 2008/096369 discloses a formulation comprising lamivudine and tenofovir DF prepared by granulating tenofovir DF seperately by dry granulation and blending the granules with extragranular lamivudine and finally compressing into tablets. This publication further discloses monolithic tablets comprising emtricitabine/lamivudine, tenofovir DF and efavirenz.
The above prior art disclose compositions of various combinations of antiretroviral agents prepared as single and/or double layered tablets. However, still there is a need to develop stable dosage form comprising lamivudine, tenofovir and efavirenz. The inventors of the present invention have surprisingly found that when lamivudine, tenofovir DF and efavirenz are granulated separately and compressed into a bilayered tablet results in a stable dosage form.
Objective of the invention
Accordingly, the main objective of the present invention is to provide a stable dosage form comprising lamivudine, tenofovir disoproxil fumarate and efavirenz and process for preparing the dosage form.
Yet another objective of the present invention is to provide stable dosage form of lamivudine, tenofovir disoproxil fumarate and efavirenz in such a way that it will comply with the reference products of each of these approved individual drugs in terms of in vitro parameters like dissolution, disintegration etc. and in vivo parameters like bioequivalence.
Summary of the invention
Accordingly, the present invention provides stable bilayered tablets comprising lamivudine, tenofovir and efavirenz prepared by wet granulation process. Detailed description of the invention
In an embodiment, the stable dosage form further comprises one or more excipients selected from diluents, binders, disintegrants, surfactants, glidants and lubricants.
Efavirenz practically insoluble in water and is freely soluble in methanol. Hence, in order to improve the solubility and thereby bioavailability, the commercially available tablets of efavirenz i.e available in the US under the
trade name Sustiva® tablets and capsules contain sodium lauryl sulfate as a solubilizer. However, the inventors of the present invention found that when tablets containing lamivudine, tenofovir and efavirenz are prepared using single step process, tenofovir degrades on storage. Initial efforts to simply combine lamivudine, tenofovir and efavirenz into a unitary composition failed to produce a chemically stable tablet. The tenofovir in this combination tablet was highly unstable and rapidly degraded in stability studies. The efavirenz formulation containing sodium lauryl sulfate was unexpectedly incompatible with tenofovir. Suitable diluents of the present invention are selected from mannitol, lactose, microcrystalline cellulose, maltitol, sorbitol, maltodextrin, maltose, starch, calcium carbonate, calcium phosphate dibasic, calcium sulfate or a combination thereof. The diluent may be used in the range of 3-50% by weight of the tablet. Suitable binders of the present invention are selected from hydroxy propyl cellulose, hydroxypropyl methylcellulose, gelatin, hydroxy ethyl cellulose, povidone, starch and methylcellulose or a combination thereof. The binder may be used in the range of 0.5-10% by weight of the tablet.
Suitable disintegrants of the present invention are selected from sodium starch glycolate, croscarmellose sodium, crospovidone, starch, hydroxypropyl cellulose, magnesium aluminum silicate, pregelatinized starch or a combination thereof. The disintegrant may be used in the range of 1-10% by weight of the tablet.
Suitable surfactants of the present invention are selected from sodium lauryl sulphate, polysorbate, sorbitan monolaurate, polyoxyethylene- polyoxypropylene block copolymer (poloxamer), polyethylene glycol derivatives, cetyl alcohol or a combination thereof. The surfactant may be used in the range of 0.01-1% by weight of the tablet.
Suitable glidants of the present invention are selected from magnesium trisilicate, talc, tribasic calcium phosphate, glyceryl monostearate, glyceryl
stearate and silica dioxide or a combination thereof. The glidant may be used in the range of 0.1-2% by weight of the tablet.
Suitable lubricants of the present invention are selected from calcium stearate, magnesium stearate, hydrogenated vegetable oil, stearic acid, magnesium aluminum silicate, sodium stearyl fumarate, glyceryl behenate or a combination thereof. The lubricant may be used in the range of 0.1-5% by weight of the tablet.
Tenofovir as used herein refers to tenofovir disoproxil fumarate. The stable bilayered tablets comprise 50-500 mg of lamivudine, 50-500 mg of tenofovir and 100-600mg of efavirenz.
In a preferred embodiment, the stable bilayered tablets comprise i) compressed granules of lamivudine, tenofovir, 2-20% w/w of diluent selected from microcrystalline cellulose, lactose and mannitol; 1-5% w/w of disintegrant selected from croscarmellose sodium, crospovidone and sodium starch glycolate prepared by wet granulation in first layer and ii) compressed granules of efavirenz, 5-20% w/w of diluent selected from microcrystalline cellulose, lactose and mannitol, 1-5% w/w of disintegrant selected from croscarmellose sodium, crospovidone and sodium starch glycolate; 0.5 to 5% w/w of binder selected form hydroxy propyl cellulose, hydroxypropyl methylcellulose, povidone; sodium lauryl sulfate in 0.1 to 2% w/w of sodium lauryl sulfate prepared by wet granulation in the second layer.
In another preferred embodiment of the invention, the stable bilayered tablets comprise i) compressed granules of lamivudine, efavirenz, 2-20% w/w of diluent selected from microcrystalline cellulose, lactose and mannitol; 1-5% w/w of disintegrant selected from croscarmellose sodium, crospovidone and sodium starch glycolate; .5 to 5% w/w of binder selected form hydroxy propyl cellulose, hydroxypropyl methylcellulose, povidone; sodium lauryl sulfate in 0.1 to 2% w/w of sodium lauryl sulfate prepared by wet granulation in the first layer and ii) compressed granules of tenofovir, 5-20% w/w of diluent selected from microcrystalline cellulose, lactose and mannitol, 1-5% w/w of disintegrant
selected from croscarmellose sodium, crospovidone and sodium starch glycolate prepared by wet granulation in the second layer.
In another embodiment of the present invention, stable bilayered tablets comprising lamivudine, tenofovir and efavirenz are prepared by wet granulation process using solvents, which comprises the steps of: a) preparing granules comprising lamivudine, tenofovir and one or more pharmaceutically acceptable excipients, b) preparing granules of efavirenz and one or more pharmaceutically acceptable excipients, c) separately blending and lubricating the granules of step (a) and (b), with extragranular excipients and d) finally compressing the granules into bi-layer tablets.
In yet another embodiment of the present invention, stable bilayered tablets comprising lamivudine, tenofovir and efavirenz are prepared by wet granulation process using solvents, which comprises the steps of: a) preparing granules comprising lamivudine, efavirenz and one or more pharmaceutically acceptable excipients, b) blending and lubricating the granules of step (a) with extragranular excipients, c) preparing granules of tenofovir and one or more pharmaceutically acceptable excipients, d) blending and lubricating the granules of step (c) with extragranular excipients, e) compressing the lubricated granules of step (b) and step (d) into bi-layer tablets.
In another embodiment of the present invention, stable bilayered tablets comprising lamivudine, tenofovir and efavirenz are prepared by wet granulation process using solvents, which comprises the steps of: a) preparing granules comprising lamivudine and one or more pharmaceutically acceptable excipients,'
b) preparing granules comprising tenofovir and one or more pharmaceutically acceptable excipients, c) preparing granules of efavirenz and one or more pharmaceutically acceptable excipients, d) blending the granules of step (a) and (b) or step (a) and (c), with extragranular excipients and e) processing the blend of (a) and (b) or (a) and (c) with the blend of (c) or (b), e) finally compressing the granules into bi-layer tablets. In another embodiment, the solvents used for granulation process may be selected from water, isopropyl alcohol, acetone, ethanol, methylene chloride or combination thereof.
In another embodiment of the present invention, the tablets of the present invention may optionally be coated to prevent the degradation of lamivudine from light with coating polymers.
Suitable film forming polymers used according to the present invention are selected from hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxy ethyl cellulose, xanthan gum and the like or a combination there of.
In another embodiment, the stable dosage form of the present invention is used for the treatment or prevention of symptoms of HIV infection in an infected individual.
The following examples further exemplify the invention and are not intended to limit the scope of the invention. It is obvious to those skilled in the art to find out the composition for other dosage forms and substitute the equivalent excipients as described in this specification or with the one known to the industry.
Comparative Example 1 Single layer tablets of lamivudine, tenofovir and efavirenz
Comparative Example 2 Single layer tablets of lamivudine, tenofovir and efavirenz
The tenofovir present in the single layer tablets of lamivudine, tenofovir and efavirenz tablets prepared to the above examples were found to be unstable. The stability data obtained after 2 months at 40°C/75% RH is shown in Table 1.
Table 1
Example 1
Bilayered tablets of lamivudine, tenofovir and efavirenz
The processing steps involved in manufacturing stable bilayered tablets of lamivudine, tenofovir and efavirenz are given below: a) preparation of granules of lamivudine plus tenofovir DF: i) sifted and blended lamivudine, tenofovir DF, microcrystalline cellulose and croscarmellose sodium, ii) granulated the blend using water, iii) dried and sized the wet mass to obtain granules,
b) preparation of granules of efavirenz: i) sifted and blended efavirenz, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, ii) granulated the blend using binder solution of hydroxypropyl cellulose, iii) dried and sized the wet mass to obtain granules, c) blending and lubrication of granules: i) the granules of lamivudine and tenofovir obtained in stage (a) were lubricated with magnesium stearate, iii) the granules of efavirenz were lubricated with magnesium stearate, iv) compressed the blends of step (i) and (ii) on bilayered compression machine, and v) coated the tablets with Opadry white.
Example 2
Bilayered tablets of lamivudine, tenofovir and efavirenz
The processing steps involved in manufacturing stable bilayered tablets of lamivudine, tenofovir and efavirenz are given below:
a) preparation of granules of lamivudine plus efavirenz: i) sifted and blended lamivudine, efavirenz, microcrystalline cellulose, croscarmellose sodium and sodium lauryl sulphate, ii) granulated the blend using binder solution of hydroxypropyl cellulose, iii) dried and sized the wet mass and lubricated the dried granules with magnesium stearate, b) preparation of granules of tenofovir disoproxil fumarate: i) sifted and blended tenofovir disoproxil fumarate, microcrystalline cellulose and croscarmellose sodium, ii) granulated the blend of step (i) using water, iii) dried and sized the wet mass and lubricated the dried granules with magnesium stearate, c) preparation of tablets: i) compressed the lubricated granules of step (a) and (b) on bilayered compression machine with lamivudine and efavirenz granules into one layer and tenofovir disoproxil fumarate granules into second layer, and ii) coated the tablets with coating agent.
Example 3
Bilayered tablets of lamivudine, tenofovir and efavirenz
The processing steps involved in manufacturing stable bilayered tablets of lamivudine, tenofovir and efavirenz are given below: a) preparation of granules of lamivudine: i) sifted and blended lamivudine, microcrystalline cellulose, croscarmellose sodium, ii) granulated the blend using binder solution of hydroxypropyl methylcellulose, iii) dried and sized the wet mass to obtain granules, b) preparation of granules of efavirenz: i) sifted and blended efavirenz, microcrystalline cellulose and croscarmellose sodium, ii) granulated the blend using binder solution of hydroxypropyl cellulose and sodium lauryl sulphate, iii) dried and sized the wet mass to obtain granules, c) preparation of granules of tenofovir disoproxil fumarate: i) sifted and blended tenofovir disoproxil fumarate, microcrystalline cellulose and croscarmellose sodium, ii) granulated the blend using binder solution of hydroxypropyl methylcellulose, iii) dried and sized the mass to obtain granules,
d) preparation of tablets: i) lubricated the granules of tenofovir disoproxil fumarate with magnesium stearate, ii) blended the lubricated tenofovir disoproxil fumarate granules with lamivudine granules along with croscarmellose sodium and again lubricated with magnesium stearate, iii) blended the granules of efavirenz with croscarmellose sodium and lubricated with magnesium stearate, iv) compressed the lubricated granules of step (ii) and (iii) on bilayered compression machine with lamivudine and tenofovir granules into one layer and efavirenz granules into second layer, and vi) coated the tablets with coating agent.
Dissolution profile of bilayered tablets of lamivudine, tenofovir and efavirenz prepared according to example 3 was carried out in water with 2% SLS as dissolution medium using USP Apparatus II with 1000 ml at 75 rpm speed. The release profile (% drug released in min) is given in Table 1.
Table 1
Example 4
Bilayered tablets of lamivudine, tenofovir and efavirenz
The processing steps involved in manufacturing stable bilayered tablets of lamivudine, tenofovir and efavirenz are given below: a) preparation of granules of lamivudine: i) sifted and blended lamivudine, microcrystalline cellulose, croscarmellose sodium, ii) granulated the blend using binder solution of hydroxypropyl methylcellulose, iii) dried and sized the wet mass to obtain granules, b) preparation of granules of efavirenz: i) sifted and blended efavirenz, microcrystalline cellulose and croscarmellose sodium, ii) granulated the blend using binder solution of hydroxypropyl cellulose and sodium lauryl sulphate, iii) dried and sized the wet mass to obtain granules,
c) preparation of granules of tenofovir disoproxil fumarate: i) sifted and blended tenofovir disoproxil fumarate, microcrystalline cellulose and croscarmellose sodium, ii) granulated the blend using binder solution of hydroxypropyl methylcellulose, iii) dried and sized the wet mass, d) preparation of tablets: i) lubricated the granules of tenofovir disoproxil fumarate with magnesium stearate, ii) blended the granules of lamivudine with croscarmellose sodium and lubricated with magnesium stearate, iii) blended the granules of efavirenz with croscarmellose sodium and lubricated with magnesium stearate, iv) mixed the lubricated granules of lamivudine and efavirenz, v) compressed the lubricated granules of step (i) and (iv) on bilayered compression machine with lamivudine and efavirenz granules into one layer and tenofovir disoproxil fumarate granules into second layer, and vi) coated the tablets with coating agent.
Dissolution profile of bilayered tablets of lamivudine, tenofovir and efavirenz prepared according to example 4 was carried out in water with 2% SLS as dissolution medium using USP Apparatus II with 1000 ml at 75 rpm speed. The release profile (% drug released in min) is given in Table 2.
Table 2
The bilayered tablets of lamivudine, tenofovir and efavirenz tablets according to the present invention were found to be stable. The stability data obtained after 1 month at 45°C/75RH is shown in Table 3.
Table 3
Lamivudine
Claims
1. A stable bilayered tablet comprising lamivudine, tenofovir and efavirenz prepared by wet granulation process.
2. The bilayered tablet as claimed in claim 1, further comprises one or more excipients selected from diluents, binders, disintegrants, surfactants, glidants and lubricants.
3. The dosage form as claimed in claim 2, wherein the diluent is selected from mannitol, lactose, microcrystalline cellulose, maltitol, sorbitol, maltodextrin, maltose, starch, calcium carbonate, calcium phosphate dibasic, calcium sulfate or a combination thereof.
4. The dosage form as claimed in claim 2, wherein the binder is selected from hydroxypropyl cellulose, hydroxypropyl methylcellulose, gelatin, hydroxy ethyl cellulose, povidone, starch and methylcellulose or a combination thereof.
5. The dosage form as claimed in claim 2, wherein the disintegrant is selected from sodium starch glycolate, croscarmellose sodium, crospovidone, starch, hydroxypropyl cellulose, magnesium aluminum silicate, pregelatinized starch or a combination thereof.
6. The dosage form as claimed in claim 2, wherein the surfactant is selected from sodium lauryl sulphate, polysorbate, sorbitan monolaurate, polyoxyethylene-polyoxypropylene block copolymer (poloxamer), polyethylene glycol derivatives, cetyl alcohol or a combination thereof.
7. The dosage form as claimed in claim 2, wherein the lubricant is selected from calcium stearate, magnesium stearate, hydrogenated vegetable oil, stearic acid, magnesium aluminum silicate, sodium stearyl fumarate, glyceryl behenate or a combination thereof.
8. A stable bilayered tablet comprising ' i) compressed granules of lamivudine, tenofovir, 2-20% w/w of diluent selected from microcrystalline cellulose, lactose and mannitol; 1-5% w/w of disintegrant selected from croscarmellose sodium, crospovidone and sodium starch glycolate prepared by wet granulation in first layer and ii) compressed granules of efavirenz, 5-20% w/w of diluent selected from microcrystalline cellulose, lactose and mannitol, 1-5% w/w of disintegrant selected from croscarmellose sodium, crospovidone and sodium starch glycolate; 0.5 to 5% w/w of binder selected form hydroxy propyl cellulose, hydroxypropyl methylcellulose, povidone; sodium lauryl sulfate in 0.1 to 2% w/w of sodium lauryl sulfate prepared by wet granulation in the second layer.
9. A stable bilayered tablet comprising i) compressed granules of lamivudine, efavirenz, 2-20% w/w of diluent selected from microcrystalline cellulose, lactose and mannitol; 1-5% w/w of disintegrant selected from croscarmellose sodium, crospovidone and sodium starch glycolate; .5 to 5% w/w of binder selected form hydroxy propyl cellulose, hydroxypropyl methylcellulose, povidone; sodium lauryl sulfate in 0.1 to 2% w/w of sodium lauryl sulfate prepared by wet granulation in the first layer and ii) compressed granules of tenofovir, 5-20% w/w of diluent selected from microcrystalline cellulose, lactose and mannitol, 1-5% w/w of disintegrant selected from croscarmellose sodium, crospovidone and sodium starch glycolate prepared by wet granulation in the second layer.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN491CH2008 | 2008-02-27 | ||
IN491/CHE/2008 | 2008-02-27 | ||
IN2135CH2008 | 2008-09-01 | ||
IN2135/CHE/2008 | 2008-09-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009106960A2 true WO2009106960A2 (en) | 2009-09-03 |
WO2009106960A3 WO2009106960A3 (en) | 2009-10-22 |
Family
ID=40688309
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2009/000352 WO2009106960A2 (en) | 2008-02-27 | 2009-02-27 | Stable compositions of lamivudine, tenofovir and efavirenz |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2009106960A2 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2854773A4 (en) * | 2012-05-31 | 2016-01-27 | Pharmascience Inc | Pharmaceutical composition of entecavir and process of manufacturing |
WO2017095761A1 (en) * | 2015-12-02 | 2017-06-08 | Merck Sharp & Dohme Corp. | Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine |
CN106822155A (en) * | 2016-12-29 | 2017-06-13 | 东北制药集团股份有限公司 | Efavirenz, Lamivudine and piece and preparation method thereof in the Compound Tablet of tenofovir disoproxil fumarate three |
WO2018028841A1 (en) * | 2016-08-12 | 2018-02-15 | Sandoz Ag | Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz |
US10857102B2 (en) | 2010-11-19 | 2020-12-08 | Gilead Sciences, Inc. | Therapeutic compositions comprising rilpivirine HCL and tenofovir disoproxil fumarate |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004089383A1 (en) * | 2003-04-14 | 2004-10-21 | Cipla Limited | Pharmaceutical combinations comprising lamivudine, stavudine and efavirenz for treating viral infections |
WO2006135933A2 (en) * | 2005-06-13 | 2006-12-21 | Bristol-Myers Squibb & Gilead Sciences, Llc | Stable fixed-dose unitary formulations containing tenofovir, a surfactant, efavirenz and emtricitabine |
WO2007068934A2 (en) * | 2005-12-14 | 2007-06-21 | Cipla Limited | Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit |
WO2008096369A2 (en) * | 2007-02-05 | 2008-08-14 | Matrix Laboratories Limited | Pharmaceutical formulation for use in hiv therapy |
-
2009
- 2009-02-27 WO PCT/IB2009/000352 patent/WO2009106960A2/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004089383A1 (en) * | 2003-04-14 | 2004-10-21 | Cipla Limited | Pharmaceutical combinations comprising lamivudine, stavudine and efavirenz for treating viral infections |
WO2006135933A2 (en) * | 2005-06-13 | 2006-12-21 | Bristol-Myers Squibb & Gilead Sciences, Llc | Stable fixed-dose unitary formulations containing tenofovir, a surfactant, efavirenz and emtricitabine |
WO2007068934A2 (en) * | 2005-12-14 | 2007-06-21 | Cipla Limited | Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit |
WO2008096369A2 (en) * | 2007-02-05 | 2008-08-14 | Matrix Laboratories Limited | Pharmaceutical formulation for use in hiv therapy |
Non-Patent Citations (2)
Title |
---|
FDA: "Guidance for Industry Fixed Dose Combination and Co-Packaged Drug Products for Treatment of HIV" INTERNET CITATION, [Online] XP002417855 Retrieved from the Internet: URL:http://www.fda.gov/oc/initiatives/hiv/hivguidance.html> [retrieved on 2007-01-31] * |
MENENDEZ-ARIAS L: "Targeting HIV: antiretroviral therapy and development of drug resistance" TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER, HAYWARTH, GB, vol. 23, no. 8, 1 August 2002 (2002-08-01), pages 381-388, XP004386181 ISSN: 0165-6147 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10857102B2 (en) | 2010-11-19 | 2020-12-08 | Gilead Sciences, Inc. | Therapeutic compositions comprising rilpivirine HCL and tenofovir disoproxil fumarate |
EP2854773A4 (en) * | 2012-05-31 | 2016-01-27 | Pharmascience Inc | Pharmaceutical composition of entecavir and process of manufacturing |
WO2017095761A1 (en) * | 2015-12-02 | 2017-06-08 | Merck Sharp & Dohme Corp. | Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine |
CN108367008A (en) * | 2015-12-02 | 2018-08-03 | 默沙东公司 | Include the pharmaceutical composition of Duola Wei Lin, tenofovir disoproxil fumarate and Lamivudine |
US10603282B2 (en) | 2015-12-02 | 2020-03-31 | Merck Sharp & Dohme Corp. | Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine |
RU2736941C2 (en) * | 2015-12-02 | 2020-11-23 | Мерк Шарп энд Доум Корп. | Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine |
US10842751B2 (en) | 2015-12-02 | 2020-11-24 | Merck Sharp & Dohme Corp. | Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine |
CN108367008B (en) * | 2015-12-02 | 2021-04-30 | 默沙东公司 | Pharmaceutical composition comprising doramevirine, tenofovir disoproxil fumarate and lamivudine |
AU2016361612B2 (en) * | 2015-12-02 | 2021-07-29 | Merck Sharp & Dohme Llc | Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine |
EP3960163A1 (en) * | 2015-12-02 | 2022-03-02 | Merck Sharp & Dohme Corp. | Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine |
WO2018028841A1 (en) * | 2016-08-12 | 2018-02-15 | Sandoz Ag | Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz |
CN106822155A (en) * | 2016-12-29 | 2017-06-13 | 东北制药集团股份有限公司 | Efavirenz, Lamivudine and piece and preparation method thereof in the Compound Tablet of tenofovir disoproxil fumarate three |
Also Published As
Publication number | Publication date |
---|---|
WO2009106960A3 (en) | 2009-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009106954A1 (en) | Stable dosage forms of lamivudine and tenofovir | |
KR102072546B1 (en) | Oral tablet formulation of lenalidomide | |
RU2376988C2 (en) | Pharmaceutical composition of slow release, containing aplindor and its derivatives | |
US10105365B2 (en) | Solid antiviral dosage forms | |
ZA200703866B (en) | Pharmaceutical formulation containing a release rate controlling compositions | |
AU2015245217A1 (en) | Unit dosage form comprising Emtricitabine, Tenofovir, Darunavir and Ritonavir | |
US10603282B2 (en) | Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine | |
WO2009106960A2 (en) | Stable compositions of lamivudine, tenofovir and efavirenz | |
EP2822560A1 (en) | Pharmaceutical antiretroviral combinations comprising lamivudine, festinavir and nevirapine | |
US20110104267A1 (en) | Pharmaceutical compositions of antiretrovirals | |
US11576917B2 (en) | Pharmaceutical compositions comprising Ibrutinib | |
US20090088424A1 (en) | Methods and compositions for controlling the bioavailability of poorly soluble drugs | |
WO2006134610A1 (en) | Efavirenz pharmaceutical composition having enhanced dissolution profile | |
US20140193491A1 (en) | Pharmaceutical antiretroviral composition | |
US10888524B2 (en) | Immediate release tablet of dofetilide | |
US20160199396A1 (en) | Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir | |
EP3326619B1 (en) | Solid oral pharmaceutical compositions comprising tenofovir and emtricitabine | |
US20150141376A1 (en) | Pharmaceutical compositions of anti-viral compounds and process for preparation thereof | |
WO2022153330A1 (en) | Pharmaceutical compositions comprising acalabrutinib | |
WO2018028841A1 (en) | Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz | |
US20150224086A1 (en) | Pharmaceutical Formulations of Rufinamide | |
WO2017029226A1 (en) | Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz | |
JP2021518422A (en) | Pharmaceutical composition containing lenalidomide | |
EP3684341A2 (en) | Pharmaceutical combinations of tenofovir, emtricitabine and efavirenz | |
JP2015503555A (en) | Bosentan controlled release oral formulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09714776 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09714776 Country of ref document: EP Kind code of ref document: A2 |